Abcellera Biologics Inc ABCL

$11.95 -0.51 (-4.09%)

Valuation

Market cap
3,820,373,000
Revenue TTM
$75,130,000
Net income TTM
$-146,410,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-194.88%
Debt to equity
0.00

Trading

Volume
2,873,600
Avg volume
4,322,906
Day's range
$11.93 – $12.95
Shares out
306,611,000
Stochastic %K
54%
Beta
1.59
Analysts
Strong Buy
Price target
$17.17

Price

Company profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-medi...

Show more

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

Industry
Biotechnology
Sector
Healthcare
Phone
604 559 9005
Website
https://www.abcellera.com
Address
150 W 4th Avenue, Vancouver, Canada

Latest news

Stocktwits

flymetothemoon2 Nov 12, 1:03 AM
$ABCL $ABCL is copying $REGN playbook to extend the possible monopoly like profits of ABCL635. Eylea, one of Regeneron’s blockbuster drugs that treats wet age-related macular degeneration and other eye conditions, had many of its core patents expire. Competition is on the horizon as generics are working towards FDA approval. How does Regeneon block the competition from eating their lunch? Develop another best in class drug. Regeneron brought to market, Elyea HD, a drug that requires less frequent dosing than Elyea. Elyea HD patents expire 2039. This strategy reminds of AbCellera’s drug ABCL992, which is a next-gen half-life extended analog of ABCL635. AbCellera announced today that they will bring ABCL992 into IND-enabling activities. Let the good times continue to roll.
0 replies
flymetothemoon2 Nov 11, 11:46 PM
$ABCL I did find carl’s remark’s noteworthy though about an argument to be made for premium product commanding a higher price.
0 replies
DeMampCamp Nov 11, 11:07 PM
$ABCL Stocktradesmoon has a new account for whatever reason. Most blocked you because you spam the shit out of the board. You can be confident in your investment AND not spam the shit out of it, people will take you much more seriously.
1 replies
flymetothemoon2 Nov 11, 9:24 PM
$ABCL $ABCL “We have a Killer product!”(ABCL635) 🤣🤣🤣🦾🔥🫶Dr. Carl Hansen @AbCelleraBio today at Stiftel conference AbCellera added three programs to its pipeline this quarter: ABCL992, a longer acting version of ABCL635 for hot flashes, ABCL385 in oncology, and ABCL646, a potential first in class ion channel antagonist. The output side keeps growing. $ABCL
0 replies
flymetothemoon2 Nov 11, 9:07 PM
$ABCL $ABCL The TAM for ABCL635 is enormous. In the past, management has said “we believe there's about a $6 billion TAM in the U.S. for non-hormonal options for the treatment of hot flashes.” They also noted how small molecule therapies currently cost upward of $5,000/yr for patients. If 635 becomes one of the best, or hands down the best option on the market, including vs hormonal, how large will the TAM be? Simple math tells me the TAM could be much larger over the long run than the original $6B management set expectations for.
1 replies
torfel86 Nov 11, 9:02 PM
$ABCL every time there are conferences this is tanking?!
1 replies
flymetothemoon2 Nov 11, 8:48 PM
$ABCL ABcellera 🧨!!!
0 replies
flymetothemoon2 Nov 11, 8:13 PM
$ABCL ❤️ ABcellera !!! 👏🔥🤑
0 replies